reports
- Carol Dou Xiao Qin
- Sunny Chen
Ping An Healthcare and Technology Company (1833 HK): 2023: Bottom line...
PAGD’s 2023 revenue declined 24.7% yoy, while adjusted net loss narrowed to Rmb315m, beating our and consensus estimates. It finished restructuring its lowsynergy businesses in 2023, and expects double-digit revenue growth for F-end and Bend strategic businesses in 2024. Its home-based elderly care services will also create new growth momentum. We expect an 18% revenue CAGR in 2023-25 with continuous strategic upgrade efforts. Maintain BUY with a target price of HK$15.00.
- Bella Lu Yifei
- Carol Dou Xiao Qin
- Ceilica Su Rui
- Greater China Research Team
- Jo Yee Ng
- Julia Pan Mengyao
- Ken Lee
- Kenny Yong Hui Lim
- Ming San Soong
- Shirley Wang Xueyi
- Stella Guo Yuting
- Sunny Chen
- Ziv Ang Sze Champ
Greater China Daily: Thursday, March 21, 2024
KEY HIGHLIGHTS Results Anhui Conch Cement (914 HK/BUY/HK$17.20/Target: HK$21.00) 2023: In line; all set to expand market share. CSPC Pharmaceutical Group (1093 HK/BUY/HK$6.41/Target: HK$7.80) 2023: Results in line; expects double-digit revenue and earnings growth in 2024. Geely Auto (175 HK/BUY/HK$8.83/Target: HK$11.00) 2023: Results beat on margins again; upgrade to BUY. Raise target price from HK$6.50 to HK$11.00. Innovent Biologics (1801 HK/BUY/HK$39.35/Target: HK$60.00) 2023: Results ...
PRU PRUDENTIAL PLC
02331 LI NING COMPANY LIMITED
00700 TENCENT HOLDINGS LTD.
0914 ANHUI CONCH CEMENT COMPANY LIMITED CLASS H
PDD PINDUODUO INC. SPONSORED ADR CLASS A
01801 INNOVENT BIOLOGICS INC.
1833 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED
1093 CSPC PHARMACEUTICAL GROUP LTD
01024 KUAISHOU TECHNOLOGY CLASS B
- Anas Fitri Bin Ahmad
- Arsit Pamaranont
- Bella Lu Yifei
- Carol Dou Xiao Qin
- Heidi Mo Jinghui
- Jack Goh Tooan Orng
- Jo Yee Ng
- Julia Pan Mengyao
- Jun Sian Tan
- Keith Wee Teck Keong
- Ken Lee
- Kenny Yong Hui Lim
- Ming San Soong
- Paula Ruth
- Shirley Wang Xueyi
- Stella Guo Yuting
- Sunny Chen
Regional Morning Notes - Thursday, March 21, 2024
GREATER CHINA Results Geely Auto (175 HK/BUY/HK$8.83/Target: HK$11.00): 2023: Results beat on margins again; upgrade to BUY. Raise target price from HK$6.50 to HK$11.00. Innovent Biologics (1801 HK/BUY/HK$39.35/Target: HK$60.00): 2023: Results beat; well positioned for sustainable growth in 2024. Kuaishou (1024 HK/BUY/HK$52.25/Target: HK$85.00): 4Q23: Resilient earnings beat; strong ad monetisation momentum continues. Li Ning (2331 HK/HOLD/HK$21.45/Target: HK$19.60): 2023: Results miss; remain c...
GRU GEELY AUTOMOBILE HOLDINGS LIMITED
PRU PRUDENTIAL PLC
02331 LI NING COMPANY LIMITED
7113 TOP GLOVE CORPORATION BHD.
TME TENCENT MUSIC
01801 INNOVENT BIOLOGICS INC.
1833 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED
01024 KUAISHOU TECHNOLOGY CLASS B
PDD PINDUODUO PDD US
EXCL XL AXIATA TBK PT
LHN LHN LTD
AIRPORT MALAYSIA AIRPORTS HOLDINGS BHD
- Carol Dou Xiao Qin
- Sunny Chen
China Healthcare: Government’s draft plan seeks to promote a more supp...
China’s draft plan is expected to develop a more efficient and supportive ecosystem for drug innovation. We believe the government will support the development of a stronger and more innovative healthcare industry by providing more financial and regulatory resources in the next few years. Facing political headwinds, leading CRDMO players may benefit from the brighter outlook of China’s healthcare industry in the longer term. Maintain MARKET WEIGHT on China’s healthcare sector.
MSK MICROPORT SCIENTIFIC CORP.
00241 ALIBABA HEALTH INFORMATION TECHNOLOGY LTD.
01177 SINO BIOPHARMACEUTICAL LIMITED
X2S SINOPHARM GROUP CO. LTD. CLASS H
3933 THE UNITED LABORATORIES INTE
2877 CHINA SHINEWAY PHARMACEUTICA
01801 INNOVENT BIOLOGICS INC.
1833 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED
300760 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO. LTD. CLASS A
603882 GUANGZHOU KINGMED DIAGNOSTICS GROUP CO. LTD. CLASS A
1093 CSPC PHARMACEUTICAL GROUP LTD
1521 FRONTAGE HOLDINGS CORP
603259 WUXI APPTEC CO. LTD. CLASS A
2269 WUXI BIOLOGICS (CAYMAN) INC.
3692 HANSOH PHARMACEUTICAL GROUP
300244 WUXI APPTEC CO. LTD. CLASS H
DIAN DIAGNOSTICS GROUP CO
PING AN HEALTHCARE sees a downgrade to Negative on account of less fun...
The independent financial analyst theScreener just lowered the general evaluation of PING AN HEALTHCARE (HK), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date March 15, 2022, the closing price was HKD 15.74 and its ta...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.